BJU International 2010-12-01

8-isoprostane F2α up-regulates the expression of type 5 phosphodiesterase in cavernosal vascular smooth muscle cells: inhibition with sildenafil, iloprost, nitric oxide and picotamide.

Matthew Hotston, Jamie Y Jeremy, Raj Persad, Jonathon Bloor, Nilima Shukla

Index: BJU Int. 106(11) , 1794-8, (2010)

Full Text: HTML

Abstract

To explore the possible role of of 8-isoprostane F(2α) (8-IPF(2α) ) in the aetiology of erectile dysfunction (ED), as the over-production of superoxide (O(2)(-)) derived from nicotinamide adenine dinucleotide phosphate (NADPH) oxidase results in the formation of 8-IPF(2α) in vascular tissue, which has similar properties to thromboxane A(2) (TXA(2) ). TXA(2) is vasoconstrictor and up-regulates the expression of NADPH oxidase and phosphodiesterase type 5 (PDE5).Cavernosal vascular smooth muscle cells (CVSMCs) were incubated with 8-IPF(2α) or the TXA(2) analogue, U46619, ±sildenafil, iloprost (a stable prostacyclin [PGI(2) ] analogue) or the nitric oxide (NO) donor NONOate for 16 h. The formation of O(2)(-) was then measured, PDE5 expression assessed using Western blotting and PGI(2) and 8-IPF(2α) formation measured using enzyme-linked immunoassays.8-IPF(2α) promoted the formation of O(2)(-) , an effect inhibited by apocynin (an NADPH oxidase inhibitor) and up-regulated the expression of PDE5. Under identical incubation conditions, 8-IPF(2α) induced an increase in the formation of 8-IPF(2α) but reduced the formation of PGI(2) . All, these effects were reversed by sildenafil, iloprost, NONOate and picotamide.These data show that O(2) (-) derived from NADPH oxidase influences the relative balance of PGI(2) and 8-IPF(2α) in CVSMCs, which in turn alters the degree of PDE5 expression. This is a novel pathogenic mechanism underlying ED and a novel mechanism of action of sildenafil.© 2010 THE AUTHORS. JOURNAL COMPILATION © 2010 BJU INTERNATIONAL.


Related Compounds

  • Picotamide

Related Articles:

Antivasoconstrictor and antiaggregatory activities of picotamide unrelated to thromboxane A2 antagonism.

1997-11-01

[Thromb. Haemost. 78(5) , 1385-91, (1997)]

Determinants of fibrinogen in an Italian population suffering from claudication. Lower fibrinogen in the south compared to middle and north of Italy. The ADEP Group.

1998-08-01

[Haematologica 83(8) , 701-7, (1998)]

Thromboxane inhibition improves renal perfusion and excretory function in severe congestive heart failure.

2003-07-02

[J. Am. Coll. Cardiol. 42(1) , 133-9, (2003)]

Treatment of aura: solving the puzzle.

2006-05-01

[Neurol. Sci. 27 Suppl 2 , S96-9, (2006)]

The receptor antagonist picotamide inhibits adrenergic and thromboxane-induced contraction of hyperplastic human prostate smooth muscle.

2013-11-15

[Am. J. Physiol. Renal Physiol. 305(10) , F1383-90, (2013)]

More Articles...